WuXi PharmaTech (WX) Tops Q4 EPS by 10c; Guides Q1, FY12 Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts WX Hot Sheet
Join SI Premium – FREE
WuXi PharmaTech (NYSE: WX) reported Q4 EPS of $0.36, $0.10 better than the analyst estimate of $0.26. Revenue for the quarter came in at $108.5 million versus the consensus estimate of $106.87 million.
Sees FY2012 revenue of $468-$488 million, versus the consensus of $464.6 million.
Sees Q1 2012 revenue of $114-$117 million, versus the consensus of $108 million.
For earnings history and earnings-related data on WuXi PharmaTech (WX) click here.
Sees FY2012 revenue of $468-$488 million, versus the consensus of $464.6 million.
Sees Q1 2012 revenue of $114-$117 million, versus the consensus of $108 million.
For earnings history and earnings-related data on WuXi PharmaTech (WX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Minerals Technologies (MTX) Tops Q3 EPS by 2c
- Portland General Electric (POR) Misses Q3 EPS by 13c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
